Patient Outcomes With Robotic-Assisted Total Knee Arthroplasty

Improved Patient Outcomes With Robotic-Assisted Total Knee Arthroplasty

This is a post-market multicentre study that has been implemented to confirm safety and performance of cemented CR/UC and PS Apex Knee implants in primary or revision Robotic Assisted Total Knee Arthroplasty up to 10-year follow up.

Study Overview

• Status: Enrolling by invitation
• Conditions: Arthroplasties, Knee Replacement; Revision Arthroplasty
• Intervention / Treatment: Device: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC; Device: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS; Device: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision

Detailed Description

This study has been implemented to confirm safety and performance of cemented CR/UC and PS Apex Knee implants in primary or revision RA-TKA up to 10-year follow up.

Prospective data will be collected for this Post Market Clinical Follow up (PMCF) study and the data will be fed into the Post-Market Surveillance (PMS) and Clinical Evaluation processes of the devices under assessment on annual basis and support presentations at orthopaedic congresses and/or peer-reviewed publication(s).

Participants will be selected for recruitment into the study from the general population of participants requiring a primary or revision knee-arthroplasty and considered suitable to receive the Apex Knee System.

• Study Type: Interventional
• Enrollment (Estimated): 713
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Flagstaff, Arizona, United States, 86001
      • Flagstaff Bone and Joint
  • Connecticut
    • Middlebury, Connecticut, United States, 06762
      • Orthopaedics New England
  • Michigan
    • Rochester,, Michigan, United States, 48307
      • DeClaire LaMacchia Orthopaedic Institute
  • New York
    • Garden City, New York, United States, 11530
      • Nyu Langone-Long Island
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73114
      • Oklahoma Sports and Orthopedics Institute
  • Wisconsin
    • La Crosse, Wisconsin, United States, 54601
      • Gundersen Health System

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patient must be a candidate for a primary or revision total knee arthroplasty
2. Patient is able and willing to sign the informed consent and follow study procedures
3. Patient's joint must be anatomically and functionally suited to receive the selected implant and accommodate use of the robotic assistance

Exclusion Criteria:

1. Patient has a BMI >45.
2. Significant neurological or musculoskeletal disorders or disease that may interfere with total knee arthroplasty survival, adversely affect gait or weight bearing, (i.e. Paget's disease, Charcot's disease, muscular dystrophy, multiple sclerosis).
3. The presence of highly communicable disease or diseases that may limit follow-up (e.g. immuno-compromised conditions, hepatitis, active tuberculosis, HIV, etc.).
4. Presence of known active metastatic or neoplastic disease.
5. Cancer patients unless they have received curative treatment and have no evidence of recurrence for 5 years.
6. Patient has a mental condition that may interfere with the subject's ability to give an informed consent or willingness to fulfill the study requirements (i.e., severe mental retardation such that the Subject cannot understand the informed consent process, global dementia, prior strokes that interfere with the Subject's cognitive abilities, senile dementia, and Alzheimer's Disease).
7. Patient has an active infection or joint sepsis.
8. Patient has muscular, neurological or vascular deficiencies which compromise the affected extremity (i.e., Parkinson's Disease, Multiple Sclerosis, and Charcot joints).
9. Patients with allergies or suspected sensitivity to any patient-contacting component of the implant to be used in the study Has known sensitivity to implants or the materials in the device including but not limited to: Ti, Al, V, Co, Cr, Mo, Ni and Si3N4.).
10. Patients who are currently on medical leave from their employment due to Worker's Compensation.
11. Patients who are at high risk for poor healing or confounding outcomes or at excessive risk for surgery (e.g., clinically significant/being actively treated for renal, hepatic, cardiac, hematologic, or neurologic disease or poorly controlled diabetes (HbA1c > 8 mg/dL) or previous history of joint infection).
12. Patients who are known drug or alcohol abusers or with psychological disorders as defined by DSM V that could affect follow-up care or treatment outcomes.
13. Patients who are currently involved in another clinical study with an investigational device.
14. Patients with current litigation pending related to medical treatment of any sort.
15. Patients, who, in the opinion of the investigator, will not be able to complete the study per the protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Revision Total Knee Arthroplasty; Sensor-assisted robotic surgery cohort with a tibia first workflow. Revision Total Knee Arthroplasty components.	Device: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision; Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex Revision knee implant type
Other: Primary Total Knee Arthroplasty; Sensor-assisted robotic surgery cohort with a tibia first workflow. Primary Total Knee Arthroplasty	Device: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC; Robotic-assisted total knee arthroplasty in femur and tibial first workflows using the BalanceBot to characterize soft tissue balance, and the Apex UltraCongruent (UC) knee implant type; Other Names: BalanceBot, Apex Knee System, Active Spacer; Device: Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS; Robotic-assisted total knee arthroplasty with a tibial first workflow using the BalanceBot to characterize soft tissue balance, and the Apex PosteriorStabilized (PS) knee implant type

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Survivorship	Frequency of device and implant related adverse events and revision surgery to be recorded.	10 Years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in KOOS from baseline to 10 years after surgery	Evaluate impact of participants knee surgery, comparing post-operative Knee Injury and Osteoarthritis Outcome Score (KOOS) Scores and participants opinion about their knee KOOS ranges from 0 - 100, in which 100 is best.	from enrolment to 10 years
Change in UCLA from baseline to 10 years after surgery	Evaluate impact of participants knee surgery, comparing post-operative Knee Injury and University of California Los Angeles (UCLA) activity Scale and measured the participants usual level of activity UCLA ranges from 0 - 10, in which the higher the score the greater the activity	from enrolment to 10 years
Change in Promis-10 from baseline to 10 years after surgery	Evaluate impact of participants knee surgery, comparing post-operative Knee Injury and Patient-Reported Outcomes Measurement Information System (PROMIS) and measures the participants physical, mental, and social health. PROMIS-10 ranges from 1 - 67, in which 67 is best.	from enrolment to 10 years

Collaborators and Investigators

• Sponsor: Corin
• Investigators: Principal Investigator: Jan A Koenig, MD, Nyu Langone-Long Island; Principal Investigator: Jeffrey H DeClaire, MD, DeClaire LaMacchia Orthopaedic Institute; Principal Investigator: Amber Randall, MD, Granite Orthopaedics; Principal Investigator: Corey Ponder, MD, Oklahoma Sports and Orthopedics Institute; Principal Investigator: John Keggi, MD, Orthopaedics New England; Principal Investigator: Jeffrey Lawrence, MD, Gundersen Lutheran Medical Foundation, Inc

Study record dates

Study Major Dates

• Study Start (Actual): November 9, 2017
• Primary Completion (Estimated): January 1, 2029
• Study Completion (Estimated): April 1, 2040

Study Registration Dates

• First Submitted: December 11, 2023
• First Submitted That Met QC Criteria: January 2, 2024
• First Posted (Actual): January 12, 2024

Study Record Updates

• Last Update Posted (Estimated): May 20, 2025
• Last Update Submitted That Met QC Criteria: May 15, 2025
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Keywords: Knee Replacement; Robotic-Assisted Total Knee Arthroplasty; Knee outcomes
• Other Study ID Numbers: CSP-2017-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No